St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the first patient implant of its 25 mm Portico™ Transcatheter Aortic Heart Valve using the Transfemoral Delivery System in its ongoing European trial. The Portico valve system offers a minimally invasive treatment option for patients with severe aortic stenosis – a narrowing of the aortic valve that obstructs blood flow from the heart.
25 mm Portico(TM) Transcatheter Aortic Heart Valve (Photo: St. Jude Medical)
The Portico Transfemoral European Trial (Portico TF EU Trial) was established to evaluate the 23 mm Portico valve, which recently received European approval, and has been expanded to include the 25 mm Portico™ valve.
A non-randomized, multi-center study, the Portico TF EU Trial will evaluate the safety and performance of the Portico 25 mm transcatheter heart valve in patients with severe aortic stenosis. The trial will enroll up to 50 patients across Europe. Data from the study will be used to support CE Mark approval.
Expanding the Portico TF EU trial to include the 25 mm Portico valve size allows physicians to increase their research of the technology in patients whose anatomy requires a larger valve size.
Made of bovine pericardial tissue, the Portico valve is attached to a self-expanding stent frame. It is the only approved transcatheter valve that can be completely resheathed (the process of bringing the valve back into the delivery catheter), repositioned at the implant site, or retrieved before being released from the delivery system.
Transcatheter heart valves like Portico are used to treat patients with severe aortic stenosis. These patients often are too sick and have co-morbidities that prevent them from having conventional open-heart valve replacement surgery. The Portico valve helps to restore normal blood flow and provides an innovative and life-saving treatment option.
During a transcatheter procedure using the transfemoral delivery system, a physician implants the Portico valve through a catheter which has been placed through a small incision in the artery of the leg in order to gain access to the heart.
“The start of the Portico TF EU Trial for the 25 mm Portico valve is another major milestone in our transcatheter valve program and an indication of our commitment to provide new options to patients suffering from aortic valvular heart disease,” said Frank J. Callaghan, president of the Cardiovascular and Ablation Technologies Division at St. Jude Medical.
The Portico Transcatheter Aortic Heart Valve and Transfemoral Delivery System are not yet approved for use in the United States. A U.S. clinical trial evaluating the Portico valve is expected to start later this year. The trial will be conducted under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE).
It is estimated that as many as 400,000 people worldwide are affected by severe aortic stenosis, a potentially life-threatening condition where the aortic heart valve becomes calcified and does not open widely enough.
For additional information about the Portico valve visit SJMPortico.com.
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended September 29, 2012. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.Business Wire
Last updated on: 04/02/2013
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.